The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1477009
SNPs in cytochromes P450 catalyzing cholesterol degradation in brain are associated with Parkinson's disease
Provisionally accepted- 1 Institut für Biochemie, Universität des Saarlandes, Saarbrücken, Saarland, Germany
- 2 Institute of Neurobiology, Bulgarian Academy of Sciences (BAS), Sofia, Sofia City, Bulgaria
- 3 Institut für Genetik, Fachbereich Biologie, Naturwissenschaftlich-Technische Fakultät, Universität des Saarlandes,, Saarbrücken, Germany
- 4 SHG Kliniken Sonnenberg Saarbrücken, Saabrücken, Germany
- 5 Institut für Medizinische Biometrie, Epidemiologie und Medizinische Informatik, Universitätsklinikum des Saarlandes, Homburg, Germany
- 6 Saarland University, Saarbrücken, Germany
Besides being an essential structural component of plasma membranes and the precursor of many functional compounds and signaling molecules cholesterol was also proposed to play a role in the etiology and/or manifestation of Parkinson's disease (PD). However, so far systematic investigations on the role of cholesterol and its metabolites present in the brain for the etiology of PD are missing. Here, we investigate for the first time the association of PD with SNPs in the genes of four cytochromes P450s (P450s), CYP46A1, CYP39A1, CYP27A1 and CYP7B1, which are critical for the degradation of cholesterol in the brain. Analyzing 1349 individuals from the PPMI data base we found 24 SNPs in these four genes, which are significantly over-or under-represented in patients suffering from idiopathic PD (IPD). Studying each of the 362 IPD patients individually, we found that most patients (45%) showed only one associated SNP in one of the four P450 genes, while 31% displayed two associated SNPs and 18% three associated SNPs. The occurrence of some associated SNPs is in the same order of magnitude as SNPs in the GBA (beta-glucocerebrosidase) and thus might reflect a genetic predisposition for PD. As all 24 SNPs were located in introns and 3' untranslated regions, we evaluated the prospective regulatory impact of the surrounding genomic regions by using transcriptome and epigenome data from the Foundational Data Initiative for Parkinson Disease (FOUNDIN-PD). FOUNDIN-PD provides gene expression, open chromatin and DNA methylation data in a cohort of 89 induced pluripotent stem cell (iPSC) lines differentiated to dopaminergic (DA) neurons derived from people in the PPMI study. Indeed, two of the 24 SNPs, one in CYP7B1 (rs118111353) and the other one in CYP27A1 (rs74446825), were localized within a region of open chromatin in differentiated neurons. Interestingly, all iPSC lines with open chromatin in rs118111353 showed the reference allele. As all four P450s, CYP46A1, CYP39A1, CYP27A1 and CYP7B1, are expressed in dopaminergic neurons, we discuss further functional studies to connect SNPs in regulatory regions with gene expression levels. Finally, potential possibilities for personalized therapeutic treatment of patients with SNPs in the four investigated P450s are discussed.
Keywords: Parkinson's disease, Cytochromes P450, CYP46A1, CYP27A1, CYP7B1, CYP39A1, Cholesterol
Received: 06 Aug 2024; Accepted: 27 Aug 2024.
Copyright: © 2024 Petkova-Kirova, Kolchina, Baas, Wagenpfeil, Unger, Schulze-Hentrich and Bernhardt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rita Bernhardt, Saarland University, Saarbrücken, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.